Systematic review of montelukast's efficacy for preventing post-bronchiolitis wheezing

Pediatric Allergy and Immunology

Volumn 25, Issue 2, 2014, Pages 143-150

  Peng, Wan Sheng ^a   Chen, Xin ^a   Yang, Xiao Yun ^a   Liu, En Mei ^b  

^a BENGBU MEDICAL COLLEGE   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Bronchiolitis; Efficacy; Meta analysis; Montelukast; Recurrent wheezing; Systematic review

Indexed keywords

CORTICOSTEROID; EOSINOPHIL PROTEIN X; MONTELUKAST; PLACEBO; ACETIC ACID DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ARTICLE; BRONCHIOLITIS; DRUG EFFICACY; HUMAN; INCIDENCE; INSOMNIA; LOW DRUG DOSE; META ANALYSIS; POSTBRONCHIOLITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENT DISEASE; RISK ASSESSMENT; VOMITING; WHEEZING; AGE; BRONCHIOLITIS, VIRAL; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD; RESPIRATORY SOUNDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY;

ACETATES; AGE FACTORS; BRONCHIOLITIS, VIRAL; CHI-SQUARE DISTRIBUTION; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; LEUKOTRIENE ANTAGONISTS; ODDS RATIO; QUINOLINES; RESPIRATORY SOUNDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896139070     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12124     Document Type: Article

References (49)

1. Everard ML. Acute bronchiolitis and croup. Pediatr Clin North Am 2009: 56: 119-33.
2. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999: 354: 541-5.
3. Sigurs N, Bjamason R, Sigurbergason F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000: 161: 1501-7.
4. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J RespirCrit Care Med 2005: 171: 137-41.
5. Kusel MM, de Klerk NH, Kebadze T, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol 2007: 119: 1105-10.
6. Dulek DE, Peebles RS Jr. Viruses and asthma. Biochim Biophys Acta 1810: 2011: 1080-90.
7. Noble V, Murray M, Webb MS, Alexander J, Swarbrick AS, Milner AD. Respiratory status and allergy nine to 10 yr after acute bronchiolitis. Arch Dis Child 1997: 76: 315-9.
8. Valkonen H, Waris M, Ruohola A, et al. Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up. Allergy 2009: 64: 1359-65.
9. Tam JS, Grayson MH. Dendritic cells, viruses, and the development of atopic disease. J Allergy 2012: 936870. doi:10.1155/2012/936870.
10. Schauer U, Hoffjan S, Bittscheidt J, et al. RSV bronchiolitis and risk of wheeze and allergic sensitization in the first year of life. Eur Respir J 2002: 20: 1277-83.
11. Da Dalt L, Callegaro S, Carraro S, et al. Nasal lavage leukotrienes in infants with RSV bronchiolitis. Pediatr Allergy Immunol 2007: 18: 100-4.
12. Han J, Jia Y, Takeda K, et al. Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus. Am J Respir Crit Care Med 2010: 182: 455-63.
13. vanSchaik SM, Tristram DA, Nagpal IS, Hinta KM, Welliver IRC, Welliver RC. Increased production of IFN-Y and cysteinylleukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999: 103: 630-6.
14. Volovitz B, Welliver RC, De Castro G, Krystofik DA, Ogra PL. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediatr Res 1988: 24: 504-7.
15. McCarthy MK, Weinberg JB. Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets. Mediators Inflamm 2012: 2012: 236345.
16. Kim CK, Koh JY, Han TH, Kim do K, Kim BI, Koh YY. Increased levels of BAL cysteinyl leukotrienes in acute RSV bronchiolitis. Acta Paediatr 2006: 95: 479-85.
17. Dimova-Yaneva D, Russell D, Main M, Brooker RJ, Helms PJ. Eosinophil activation and cysteinyl leukotriene production in infants with respiratory syncytial virus bronchiolitis. Clin Exp Allergy 2004: 34: 555-8.
18. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics 2001: 107: 381-90.
19. Montuschi P. Leukotrienes, Antileukotrienes and Asthma. Mini Rev Med Chem 2008: 8: 647-56.
20. ColochoZelaya EA, Orvell C, Strannegard O. Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus. Pediatr Allergy Immunol 1994: 5: 100-6.
21. Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. Respiratory syncytial virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med 1999: 159: 1918-24.
22. Ehlenfield DR, Cameron K, Welliver RC. Eosinophilia at the time of respiratory syncytial virus bronchiolitis predicts childhood reactive airway disease. Pediatrics 2000: 105: 79-83.
23. Blom DJ, Ermers M, Bont L, van Woensel JB, Van Aalderen WM. Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. Cochrane Database Syst Rev 2011: 1: CD004881.
24. Montuschi P. Peters-Golden MLLeukotriene modifiers for asthma treatment. Clin Exp Allergy 2010: 40: 1732-41.
25. Meliton AY, Muñoz NM, Osan CM, Meliton LN, Leff AR. Leukotriene D4 activates {beta}2-integrin adhesion in human polymorphonuclear leukocytes. Eur Respir J 2010: 35: 402-9.
26. Montuschi P, Mondino C, Koch P, Ciabattoni G, Barnes PJ, Baviera G. Effects of montelukast treatment and withdrawal on fractional exhaled nitric oxide and lung function in children with asthma. Chest 2007: 132: 1876-81.
27. Bisgaard H, Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus post bronchiolitis. Am J Respir Crit Care Med 2003: 167: 379-83.
28. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org
29. Bai J, Xu PR. Montelukast in the treatment of bronchiolitis, a multi-center, randomized, three-blind, placebo-controlled trial. Chin J Evid-based Med 2010: 10: 1011-5.
30. Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008: 178: 854-60.
31. Kim CK, Choi J, Kim HB, et al. A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation. J Pediatr 2010: 156: 749-54.
32. Proesmans M, Sauer K, Govaere E, Raes M, Bilderling GD, Boeck KD. Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis. Acta Paediatr 2009: 98: 1830-4.
33. Montuxchi P. Pharmacotherapy of patients with mild persistent asthma: strategies and issue. Front Pharmacol 2011: 2: 35.
34. Montuschi P, Barnes PJ. New perspectives in pharmacological treatment of mild persistent asthma. Drug Discov Today 2011: 16: 1084-91.
35. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6 to 14 year old children. JAMA 1998: 279: 1181-6.
36. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001: 108: E48.
37. Bisgaard H, Zielen S, Garcia ML, et al. Montelukast reduces asthma exacerbations in 2 to 5 year old children with intermittent asthma. Am J Respir Crit Care Med 2005: 171: 315-22.
38. Hakim F, Vilozni D, Adler A, Livnat G, Tal A, Bentur L. The effect of montelukast on bronchial hyperreactivity in preschool children. Chest 2007: 131: 180-6.
39. Bisgaard H, Nielsen KG. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am J Respir Crit Care Med 2000: 162: 187-90.
40. van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability, and exploratory efficacy of montelukast in 6 to 24 month old patients with asthma. Curr Med Res Opin 2005: 21: 971-9.
41. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009: 44: 568-79.
42. Montella S, Maglione M, De Stefano S, Manna A, Di Giorgio A, Santamaria F. Update on leukotriene receptor antagonists in preschool children wheezing disorders. Ital J Pediatr 2012: 38: 29.
43. Capristo C, Rigotti E, Boner AL. Update on the use of montelukast in pediatric asthma. Allergy Asthma Proc 2006: 27: 312-8.
44. Pelkonen AS, Malmström K, Sarna S, et al. The effect of montelukast on respiratory symptoms and lung function in wheezy infants. Eur Respir J 2013: 41: 664-70.
45. Venge P. Monitoring the allergic inflammation. Allergy 2004: 59: 26-32.
46. Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008: 38: 709-50.
47. Kim CK, Seo JK, Ban SH, Fujisawa T, Kim DW, Callaway Z. Eosinophil-derived neurotoxin levels at 3 months post-respiratory syncytial virus bronchiolitis are a predictive biomarker of recurrent wheezing. Biomarkers 2013: 18: 230-5.
48. Garofalo R, Kimpen JL, Welliver RC, Ogra PL. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus. J Pediatr 1992: 120: 28-32.
49. Abu-Ghazaleh RI, Dunnette SL, Loegering DA, et al. Eosinophil granule proteins in peripheral blood granulocytes. J Leukoc Biol 1992: 52: 611-8.